Fig. 2: Verification of sEVs isolated from pooled serum and sEVs from PTMC patients promoted PTC cell proliferation and migration. | Cancer Gene Therapy

Fig. 2: Verification of sEVs isolated from pooled serum and sEVs from PTMC patients promoted PTC cell proliferation and migration.

From: Serum small extracellular vesicles-derived BST2 as a biomarker for papillary thyroid microcarcinoma promotes lymph node metastasis

Fig. 2: Verification of sEVs isolated from pooled serum and sEVs from PTMC patients promoted PTC cell proliferation and migration.

A Transmission electron micrographs (TEM) of sEVs; scale bar: 100 nm. B Representative nanoparticle tracking analysis (NTA) profiles of sEVs from one serum sample. C CD9, TSG101, CD63, CD81, and Calnexin (common sEV-enriched markers) immunoblots of BN-sEVs, NLNM-sEVs, and LNM-sEVs. D After incubation with sEVs (50 µg/ml) and PBS (negative control) for 96 h, the proliferation of PTC cell lines (BCPAP and KTC-1) was measured by cell counting kit-8 assay (*sEVs vs PBS, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; #P < 0.05, ###P < 0.001, ####P < 0.0001). E The cell migration of PTC cell lines (BCPAP and KTC-1) in response to sEVs (50 µg/ml) or negative control was determined. scale bar: 100 µm (*sEVs vs PBS, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ##P < 0.01, ###P < 0.001, ####P < 0.0001). F The HLEC cell migration and lymph tube formation response to sEVs and negative control are shown. (*sEVs vs PBS, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ##P < 0.01, ###P < 0.001, ####P < 0.0001); Scale bar: 100 µm. Error bars represent standard deviations.

Back to article page